Silencing of CCL5 in TAMs inhibits bone metastasis and self‐renewal of PCSCs in vivo and therefore TAMs/CCL5 can be a novel target in predicting prognosis of prostate cancer and inhibiting metastasis.138. Here, CCL5 is linked to prostate cancer.